Trial Profile
Phase I safety and acceptability study of the vaginal microbicide agent PMPA [tenofovir] gel.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 16 Feb 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 16 Feb 2012 Planned number of patients changed from 96 to 120 as reported by ClinicalTrials.gov.
- 01 Dec 2006 Status change